Tenofovir Is Associated With a Better Prognosis Than Entecavir for Hepatitis B Virus–Related Hepatocellular Carcinoma,Clinical Gastroenterology and Hepatology

当前位置： X-MOL 学术 › Clin. Gastroenterol. Hepatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Tenofovir Is Associated With a Better Prognosis Than Entecavir for Hepatitis B Virus–Related Hepatocellular Carcinoma
Clinical Gastroenterology and Hepatology ( IF 11.6 ) Pub Date : 2024-07-31 , DOI: 10.1016/j.cgh.2024.07.013
Sung Won Chung ₁ , Hyun Jun Um ₁ , Won-Mook Choi ₁ , Jonggi Choi ₁ , Danbi Lee ₁ , Ju Hyun Shim ₁ , Kang Mo Kim ₁ , Young-Suk Lim ₁ , Han Chu Lee ₁

Affiliation

Whether tenofovir or entecavir has different effects on the prevention of hepatitis B virus (HBV)–related hepatocellular carcinoma (HCC) in secondary and tertiary preventive settings is still a matter of debate. This study aimed to compare the long-term prognosis of HCC between tenofovir and entecavir in patients with chronic hepatitis B.

中文翻译：